Auro Laboratories Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Auro Laboratories Ltd is ₹ 261.5 as of 06 May 15:30 . The P/E Ratio of Auro Laboratories Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 45 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Auro Laboratories Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 2637 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Auro Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 178.34 crore as compare to the Mar '25 revenue of ₹ 125.98 crore. This represent the growth of 41.56% The ebitda of Auro Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 57.79 crore as compare to the Mar '25 ebitda of ₹ 31.21 crore. This represent the growth of 85.17% The net profit of Auro Laboratories Ltd changed from ₹ 0.75 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 10.91 crore to ₹ 33.58 crore over 7 quarters. This represents a CAGR of 90.11% The Dividend Payout of Auro Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Auro Laboratories Ltd

Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

FAQs for the comparison of Auro Laboratories Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, Auro Laboratories Ltd or Senores Pharmaceuticals Ltd?

Market cap of Auro Laboratories Ltd is 162 Cr while Market cap of Senores Pharmaceuticals Ltd is 4,229 Cr

What are the key factors driving the stock performance of Auro Laboratories Ltd and Senores Pharmaceuticals Ltd?

The stock performance of Auro Laboratories Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Auro Laboratories Ltd and Senores Pharmaceuticals Ltd?

As of May 6, 2026, the Auro Laboratories Ltd stock price is INR ₹261.5. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹918.35.

How do dividend payouts of Auro Laboratories Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of Auro Laboratories Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.